SEC Filing Summary: 180 Life Sciences Corp. (ATNF)
Business Context and Reporting Period
This Form 8-K was filed on July 23, 2024, by 180 Life Sciences Corp. (the "Company"), a Delaware corporation. The report addresses a specific event regarding the Company's listing status on The NASDAQ Stock Market LLC. The Company's principal executive offices are located in Palo Alto, California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding listing standards rather than operational financial performance.
Material Changes and Events
- Nasdaq Compliance Extension: The Company received an additional extension from a Hearing Panel of the Nasdaq Stock Market LLC.
- Compliance Deadline: The extension grants the Company until September 30, 2024, to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.
- Listing Status: The Company's Common Stock (ATNF) and Warrants (ATNFW) remain registered on The NASDAQ Stock Market LLC.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release dated July 23, 2024. The primary risk highlighted is the potential loss of listing status on the Nasdaq Capital Market if the Company fails to meet the minimum stockholders' equity requirement by the September 30, 2024 deadline. No forward-looking financial guidance or management commentary on operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance against the Nasdaq minimum requirement.
- Confirm the specific terms of the extension granted by the Nasdaq Hearing Panel.
- Monitor subsequent filings for updates on compliance status prior to the September 30, 2024 deadline.
- Review the full text of the press release (Exhibit 99.1) for any additional details on the Company's plan to regain compliance.